Program
Glycopyrrolate
Also written as “NVA237”, “BGF MDI 320/14.4/9.6 μg” and “GFF MDI (PT003)”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma · Hyperhidrosis · Renal Insufficiency, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 291 open or running | phase 4since Aug 9, 2013 | Jul 13, 2007 | Jul 30, 2027phase 2 · NCT05222529 |
| Chiesi Farmaceutici | 150 open or running | phase 3since Aug 5, 2013 | Aug 5, 2010 | none ahead |
| Sumitomo Pharma | 30 open or running | phase 2since Oct 26, 2016 | Jul 24, 2015 | none ahead |
| Journey Medical | 20 open or running | phase 2since Dec 16, 2013 | Dec 16, 2013 | none ahead |
| Dr. August Wolff GmbH & Co. KG Arzneimittel | 10 open or running | phase 2since Apr 27, 2023 | Apr 27, 2023 | none ahead |
| NIOX Group | 10 open or running | phase 2since Oct 4, 2012 | Oct 4, 2012 | none ahead |
| sosei | 10 open or running | phase 2since Oct 19, 2005 | Oct 19, 2005 | none ahead |
Also a collaborator on its studies: parexel, iqvia-pty-ltd, premier-inc, ciscrp and eresearchtechnology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 37 studies since Oct 19, 2005.
- Jul 2, 2014Phase 2 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT02189577 · 100 enrolled · Bulgaria, Germany, Poland and more
- Nov 14, 2014Phase 2 study in AsthmaChiesi Farmaceutici · NCT02296411 · 98 enrolled · Bulgaria, Germany, Italy and more
- Feb 19, 2015Phase 4 study in Pulmonary Disease, Chronic ObstructiveNovartis · NCT02371629 · 776 enrolled · Belgium, Bulgaria, Finland and more
- Jul 24, 2015Sumitomo Pharma's first study: phase 1 study in Pulmonary Disease, Chronic ObstructiveNew to Sumitomo PharmaSumitomo Pharma · NCT02512302 · 30 enrolled · United Kingdom
- Oct 26, 20162 phase 2 studies in Pulmonary Disease, Chronic ObstructiveSumitomo Pharma · NCT02951312, NCT02948582
- Nov 15, 2016Phase 1 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT02975843 · 28 enrolled
- Mar 8, 2017Phase 2 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT03084796 · 733 enrolled · United States
- Apr 24, 2017Phase 3 study in AsthmaNovartis · NCT03137784 · 148 enrolled · United States, Belgium, Germany and more
- Aug 23, 2017Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT03268226 · 20 enrolled · Belgium, Hungary
- Mar 23, 2020Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT04320342 · 3,406 enrolled · United States, Argentina, Bulgaria and more
- May 3, 2021Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT04876677 · 25 enrolled · Belgium, Hungary
- Jan 10, 2022Phase 2 study in AsthmaNovartis · NCT05222529 · 42 planned · Bulgaria, Colombia, Guatemala and more
- Mar 28, 2023Phase 1 study in AsthmaChiesi Farmaceutici · NCT05830071 · 95 enrolled · United States
- Apr 27, 2023Dr. August Wolff GmbH & Co. KG Arzneimittel's first study: phase 2 study in HyperhidrosisNew to Dr. August Wolff GmbH & Co. KG ArzneimittelDr. August Wolff GmbH & Co. KG Arzneimittel · NCT05863104 · 44 enrolled · Germany
Ahead
- Jul 30, 2027Primary completion: phase 2 study in AsthmaNovartis · NCT05222529
TargetBeta
“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor”ChEMBL 37, by rule
Studies
All 52 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05863104Hyperhidrosis · Germany | 2 | Completed | Dr. August Wolff GmbH & Co. KG Arzneimittel | Mar 6, 2024 | 44 |
| NCT05830071Asthma · United States | 1 | Completed | Chiesi Farmaceutici | Oct 13, 2023 | 95 |
| NCT05222529Asthma · Bulgaria, Colombia, Guatemala and more | 2 | Recruiting | Novartis | Jul 30, 2027 | 42 |
| NCT04876677Pulmonary Disease, Chronic Obstructive · Belgium, Hungary | 3 | Completed | Chiesi Farmaceutici | Jan 3, 2022 | 25 |
| NCT04320342Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more | 3 | Completed | Chiesi Farmaceutici | Jan 12, 2026 | 3,406 |
| NCT03268226Pulmonary Disease, Chronic Obstructive · Belgium, Hungary | 3 | Completed | Chiesi Farmaceutici | Jan 30, 2019 | 20 |
| NCT03137784Asthma · United States, Belgium, Germany and more | 3 | Completed | Novartis | Dec 29, 2017 | 148 |
| NCT03084796Pulmonary Disease, Chronic Obstructive · United States | 2 | Completed | Chiesi Farmaceutici | May 23, 2018 | 733 |
| NCT02975843Pulmonary Disease, Chronic Obstructive | 1 | Completed | Chiesi Farmaceutici | Mar 21, 2017 | 28 |
| NCT02951312Pulmonary Disease, Chronic Obstructive | 2 | Completed | Sumitomo Pharma | Jul 2009 | 12 |
| NCT02948582Pulmonary Disease, Chronic Obstructive | 2 | Completed | Sumitomo Pharma | Nov 2010 | 42 |
| NCT02512302Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Completed | Sumitomo Pharma | Apr 2016 | 30 |
| NCT02371629Pulmonary Disease, Chronic Obstructive · Belgium, Bulgaria, Finland and more | 4 | Completed | Novartis | Nov 16, 2016 | 776 |
| NCT02296411Asthma · Bulgaria, Germany, Italy and more | 2 | Completed | Chiesi Farmaceutici | Aug 13, 2015 | 98 |
| NCT02189577Pulmonary Disease, Chronic Obstructive · Bulgaria, Germany, Poland and more | 2 | Completed | Chiesi Farmaceutici | Feb 2015 | 100 |
| NCT02202616Pulmonary Disease, Chronic Obstructive · Canada | 4 | Completed | Novartis | Apr 5, 2017 | 401 |
| NCT02129660Hyperhidrosis · United States, Canada | 2 | Completed | Journey Medical | Jan 2015 | 105 |
| NCT02127697Asthma | 3 | Withdrawn | Novartis | May 2017 | 0 |
| NCT02119234Pulmonary Disease, Chronic Obstructive · Poland | 1 | Completed | Chiesi Farmaceutici | Feb 2015 | 36 |
| NCT02040597Pulmonary Disease, Chronic Obstructive · Poland | 1 | Completed | Chiesi Farmaceutici | Apr 2015 | 42 |
| NCT02016885Hyperhidrosis · United States | 2 | Completed | Journey Medical | Sep 2014 | 198 |
| NCT01985334Pulmonary Disease, Chronic Obstructive · Austria, Belgium, Czechia and more | 4 | Completed | Novartis | Apr 29, 2016 | 4,389 |
| NCT01959516Pulmonary Disease, Chronic Obstructive · Germany, Italy, Spain and more | 4 | Completed | Novartis | Oct 2014 | 124 |
| NCT01922271Pulmonary Disease, Chronic Obstructive · Germany | 4 | Completed | Novartis | Jan 2014 | 152 |
| NCT01917331Pulmonary Disease, Chronic Obstructive · Hungary | 3 | Completed | Chiesi Farmaceutici | Jan 14, 2016 | 1,368 |
| NCT01837927Pulmonary Disease, Chronic Obstructive | 3 | Withdrawn | Novartis | Apr 2016 | 0 |
| NCT01757015Pulmonary Disease, Chronic Obstructive | 3 | Withdrawn | Novartis | Apr 2014 | 0 |
| NCT01715298Pulmonary Disease, Chronic Obstructive · United States | 3 | Completed | Novartis | Dec 2013 | 432 |
| NCT01709864Pulmonary Disease, Chronic Obstructive · United States | 3 | Completed | Novartis | Oct 2013 | 440 |
| NCT01703624Pulmonary Disease, Chronic Obstructive · United Kingdom | 2 | Completed | NIOX Group | Aug 2013 | 37 |
| NCT01699685Pulmonary Disease, Chronic Obstructive · Switzerland | 3 | Completed | Novartis | Jun 2014 | 79 |
| NCT01697696Pulmonary Disease, Chronic Obstructive · United States | 3 | Completed | Novartis | Nov 2014 | 511 |
| NCT01613690Renal Insufficiency · Russian Federation | 1 | Completed | Novartis | Nov 2010 | 48 |
| NCT01604278Pulmonary Disease, Chronic Obstructive · Belgium, Bulgaria, Greece and more | 3 | Completed | Novartis | Jan 2013 | 449 |
| NCT01566604Pulmonary Disease, Chronic Obstructive · China, India, Korea, Republic of and more | 3 | Completed | Novartis | Jun 2013 | 460 |
| NCT01613326Pulmonary Disease, Chronic Obstructive · Canada, Croatia, Czech Republic and more | 3 | Completed | Novartis | Jan 2013 | 657 |
| NCT01513460Pulmonary Disease, Chronic Obstructive · Australia, New Zealand | 3 | Completed | Novartis | Dec 2013 | 773 |
| NCT01476813Pulmonary Disease, Chronic Obstructive · United Kingdom | 2 | Completed | Chiesi Farmaceutici | Sep 2012 | 281 |
| NCT01398111Pulmonary Disease, Chronic Obstructive · Belgium | 1 | Completed | Chiesi Farmaceutici | Aug 2011 | 44 |
| NCT01176903Pulmonary Disease, Chronic Obstructive · United Kingdom | 2 | Completed | Chiesi Farmaceutici | Nov 2010 | 65 |
| NCT01176851Healthy · United Kingdom | 1 | Completed | Chiesi Farmaceutici | Oct 2010 | 20 |
| NCT01154127Pulmonary Disease, Chronic Obstructive · United States, Germany, Italy and more | 3 | Completed | Novartis | Feb 2011 | 108 |
| NCT01119950Pulmonary Disease, Chronic Obstructive · United States, Belgium, Germany and more | 2 | Completed | Novartis | Dec 2010 | 388 |
| NCT01119937Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | Novartis | Nov 2011 | 211 |
| NCT01005901Pulmonary Disease, Chronic Obstructive · United States, Australia, Canada and more | 3 | Completed | Novartis | Dec 2010 | 1,324 |
| NCT00929110Pulmonary Disease, Chronic Obstructive · United States, Argentina, Canada and more | 3 | Completed | Novartis | Apr 2011 | 1,066 |
| NCT00856193Pulmonary Disease, Chronic Obstructive · United States, Germany | 2 | Completed | Novartis | May 2009 | 33 |
| NCT00558285Pulmonary Disease, Chronic Obstructive · Australia, Belgium, Canada and more | 2 | Completed | Novartis | Jul 2008 | 257 |
| NCT00545311Pulmonary Disease, Chronic Obstructive · Denmark, Germany | 1 | Completed | Novartis | 40 | |
| NCT00510510Pulmonary Disease, Chronic Obstructive · United States, France, Germany and more | 2 | Completed | Novartis | Jan 2008 | 281 |
| NCT00501852Pulmonary Disease, Chronic Obstructive · Belgium, France, Japan | 2 | Completed | Novartis | Dec 2007 | 83 |
| NCT00242333Pulmonary Disease, Chronic Obstructive · Bulgaria, Hungary, Poland and more | 2 | Completed | sosei | 300 |
How it is read
Names in the registry
- “NVA237”, 20 entries
- “Glycopyrrolate”, 8 entries
- “BGF MDI 320/14.4/9.6 μg”, 6 entries
- “GFF MDI (PT003)”, 6 entries
- “Indacaterol maleate and glycopyrronium bromide”, 4 entries
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 71 studies
- Asthma, 7 studies
- Hyperhidrosis, 3 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.